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Abstract
Background: The anti-inflammatory effects of the selective phosphodiesterase (PDE) inhibitors
cilostazol (PDE 3), RO 20-1724 (PDE 4) and sildenafil (PDE 5) were examined in a murine model
of allergic asthma. These compounds were used alone and in combination to determine any
potential synergism, with dexamethasone included as a positive control.
Methods: Control and ovalbumin sensitised Balb/C mice were administered orally with each of
the possible combinations of drugs at a dose of 3 mg/Kg for 10 days.
Results: When used alone, RO 20-1724 significantly reduced eosinophil influx into lungs and
lowered tumour necrosis factor-α, interleukin-4 and interleukin-5 levels in the bronchoalveolar
lavage fluid when compared to untreated mice. Treatment with cilostazol or sildenafil did not
significantly inhibit any markers of inflammation measured. Combining any of these PDE inhibitors
produced no additive or synergistic effects. Indeed, the anti-inflammatory effects of RO 20-1724
were attenuated by co-administration of either cilostazol or sildenafil.
Conclusions: These results suggest that concurrent treatment with a PDE 3 and/or PDE 5
inhibitor will reduce the anti-inflammatory effectiveness of a PDE 4 inhibitor.
Background
The cyclic nucleotides, cAMP and cGMP are important
second messengers known to control many cellular proc-
esses, such as inflammation. The cyclic nucleotide signal-
ling system is both complex and interlinked with many
other pathways [1], their signals being tightly controlled
by regulating the synthesis and breakdown of these mole-
cules. The only means the cell possesses to degrade the sig-
nal mediated by cyclic nucleotides is through the action of
a large family of enzymes, the cyclic nucleotide phos-
phodiesterases [2].
To date, 11 PDE families have been identified. As these
can be derived from multiple genes, many capable of
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generating a number of isoforms, there currently exists
over 50 known PDE enzymes [3-6]. Differences in tissue
expression patterns and spatial compartmentalisation
within cells resulting in unique functional roles, and con-
trolling mechanisms, is believed to explain the require-
ment for a large number of enzymes performing a similar
process.
Their great diversity, and key role in controlling cyclic
nucleotide signalling, makes the PDE family attractive
drug targets. In recent years, a number of inhibitors of
these enzymes have been brought to the market. Examples
of these are the PDE 3 inhibitor, cilostazol, for the treat-
ment of intermittent claudication [7], and sildenafil, a
PDE 5 inhibitor, for the treatment of sexual dysfunction
[8]. The PDE 4 family has also been extensively investi-
gated, as inhibitors of these enzymes are known to be
both potent anti-depressants and anti-inflammatory
agents [9,10]. To date, side effects have prevented PDE4
inhibitors being used commercially, however, a number
of groups now appear near to market with specific inhibi-
tors for the treatment of airway diseases [11-13].
Extensive studies using specific inhibitors both in vitro and
in vivo have demonstrated the regulation of airway
smooth muscle by cAMP specific PDE 3 and PDE 4 fami-
lies [14-16]. Members of both families are also expressed
in cells of the immune system and considerable attention
has been focussed on the potential of selective inhibitors
of PDE 3 and PDE 4, or in combination, for the treatment
of asthma and other inflammatory diseases [17-21]. In
contrast, despite the presence of the cGMP hydrolysing
PDE 5 in airways, the potential anti-inflammatory actions
of selective inhibitors has not been fully investigated.
It has been reported that not only do PDE 3 and PDE 4
inhibitors induce relaxation of airways [22], a combined
inhibition of both may produce a more potent anti-
inflammatory effect than single inhibition of either alone
[23]. In human alveolar macrophages, endotoxin-induced
release of TNF-α is only completely inhibited by a combi-
nation of the PDE 3 inhibitor, motapizone, and the PDE
4 inhibitor, rolipram [24]. In passively sensitised human
airways, allergen-induced contraction was inhibited only
by the simultaneous inhibition of PDE 3 and PDE 4 and
not by single inhibition of either family [25]. Further-
more, ovalbumin-induced pulmonary eosinophil influx
in guinea pigs was attenuated more effectively by a mixed
PDE 3/4 inhibitor than by either a selective PDE 3 or PDE
4 inhibitor [23,26]. Whether this synergistic relationship
is unique to PDE 3 and PDE 4 alone, or if combinations
of other PDE inhibitors will produce similar increases in
anti-inflammatory activity, remains to be seen. Interest-
ingly, in an in vivo model of pulmonary resistance, the
PDE 3 inhibitor, milrinone, and the PDE 5 inhibitor, zap-
rinast offer a synergistic effect when used in combination
[27]. To date, however, very little is known regarding the
potential interaction between selective inhibitors of PDE
3, PDE 4 and PDE 5.
With PDE inhibitors becoming more commonly used to
treat disease, our study sought to determine the effects
that combinations of inhibitors may have upon the anti-
inflammatory effects of a PDE 4 inhibitor. Therefore, we
investigated the abilities of a PDE 3 selective inhibitor
(cilostazol), a PDE 4 selective inhibitor (RO 20-1724) and
a PDE 5 selective inhibitor (sildenafil), to inhibit inflam-
mation in a murine model of allergic asthma [28]. The
effectiveness of these drugs was evaluated when adminis-
tered alone and in combination. These results suggest that
co-administration of a PDE 3 and/or PDE 5 inhibitor may
reduce the anti-inflammatory effectiveness of a PDE 4
inhibitor.
Methods
Animals
Male Balb/c mice, 6 weeks old on arrival and weighing
20–25 g, were obtained from B&K Universal. The mice
were housed for 10 days prior to the beginning of the
study. The mice were provided with standard laboratory
chow and tap water ad libitum. Animals were maintained
on a 12-h light/dark cycle at appropriate humidity and
temperature levels. Protocols used in this study were
approved by the appropriate ethical committees. The ani-
mals used in this study were placed into 2 experimental
blocks of 40 mice, staggered 1 day apart. Each experimen-
tal block consisted of all groups (4 mice/group) with both
data sets merged at the end of the study. To avoid experi-
mental bias mice were sacrificed, 1 animal per group,
until all groups had been processed and then repeated 4
times.
Allergen sensitisation, challenge and dosing
Mice were sensitised by the administration of two intra-
peritoneal injections, twelve days apart (Day 0 and 12), of
50 µg of ovalbumin (OVA; Grade V, Sigma) with 1 mg of
Aluminium hydroxide in 0.5 ml sterile saline (0.9%
sodium chloride). Ten, fourteen and eighteen days after
the last immunisation (Days 22, 26 and 30), mice were
challenged for 30 minutes with an aerosol of ovalbumin
generated from a 1% solution (wt/v) of ovalbumin in ster-
ile saline using an ultrasonic nebulizer. Control animals
were challenged with aerosolised sterile saline only. The
inhibitors cilostazol (PDE 3), RO 20-1724 (PDE 4) and
sildenafil (PDE 5) were dissolved in sterile saline solution
containing 0.1% (v/v) Tween 20 (Sigma) and adminis-
tered alone or in combination (Table 1). The glucocorti-
coid, dexamethasone-21-phosphate, di-sodium salt
(Sigma) was also dissolved in sterile saline solution con-
taining 0.1% (v/v) Tween 20. Drugs were administered byRespiratory Research 2004, 5 http://respiratory-research.com/content/5/1/4
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oral gavage daily for the final ten days of the sensitisation
protocol (Days 20–30). All drugs were administered to
give a final dose of 3 mg/Kg body weight, an effective,
common dose used in similar studies.
Bronchoalveolar lavage and serum collection
Twenty-four hours after the last ovalbumin challenge,
mice were sacrificed with an overdose of sodium penta-
barbitone (Rhone Meroux). Blood was obtained by car-
diac puncture prior to bronchoalveolar lavage being
performed. The collected blood was centrifuged at 13,225
g for 10 min before the serum was collected and stored at
-80°C. Mice were then lavaged by cannulating the trachea
and instilling 1.0 ml of sterile saline, twice with the same
solution. The lavage was repeated with a second 1.0 ml of
sterile saline. The lavage fluid was then centrifuged at 400
g for 10 min at 4°C. The supernatant from the first lavage
was stored at -80°C for subsequent biological analysis.
The cell pellets from both lavages were combined and
resuspended in 0.5 ml RPMI 1640 media (Sigma) supple-
mented with 5% Foetal Calf Serum (PAA Laboratories).
The cell suspension (10 ul) was mixed with Turk's solu-
tion (Gift from Kyorin Pharmaceutical Co Ltd) in a 1:1
ratio before the total cell number was then calculated by
way of haemocytometer. Cytospin preparations of the
bronchoalveolar lavage (BAL) cells were prepared in
duplicate for each sample (Cytospin 3; Shandon). The
slides were then fixed and stained with Quick Stain (Ray-
mond Lamb) to allow differentiation between cell types.
Differential counts were based on at least 200 cells per
slide, using standard morphologic criteria to identify cells
as monocytes, eosinophils or neutrophils.
Serum IgE assay
Serum IgE was determined using an ELISA kit purchased
from BD biosciences (Kit No – 555248).
Measurement of inflammatory cytokines
Levels of TNF-α, IL-4 and IL-5 in BAL fluid were deter-
mined using a Bioplex protein array system (Biorad) with
matched antibody pairs for murine TNF-α, IL-4 and IL-5.
Measurement of phosphodiesterase activity
PDE activity was determined by a modification of the 2-
step procedure by Thompson and Applegate, 1971 [29]
adapted to a 96 well plate format.
Statistical analysis
Groups were analysed using one-way analysis of variance
with Dunnett's Multiple Comparison Test (GraphPad
Prism). Differences were considered significant if p < 0.05.
Values for all measurements are expressed as mean ± SEM.
Table 1: Drug treatment for experimental study groups
Study Group Drug PDE Inhibition
A Saline -
B Saline -
C Cilostazol 3
D RO 20-1724 4
E Sildenafil 5
F Cilostazol + RO 20-1724 3 + 4
G Cilostazol + Sildenafil 3 + 5
H RO 20-1724 + Sildenafil 4 + 5
I Cilostazol + RO 20-1724 + Sildenafil 3 + 4 + 5
J Dexamethasone -
Table 2: Inhibitory potency (µM) of study compounds against cloned human PDE's. Measurements were determined by a modification 
of the 2 step procedure described by Thompson and Applegate (1971).
PDE 3 (IC50) PDE 4 (IC50)P D E  5  ( I C 50)
Cilostazol 3.7 >100 Nil
Ro 20-1724 Nil 1.3 Nil
Sildenafil Nil Nil 0.061Respiratory Research 2004, 5 http://respiratory-research.com/content/5/1/4
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Results
Cellular analysis of BAL fluid
Total leukocyte numbers
Total leukocyte numbers were significantly (p < 0.001)
increased in OVA-challenged mice compared to non-OVA
challenged mice (Group A; Figure 1A, Table 3) and mark-
edly inhibited by Dexamethasone (p < 0.01).
When used alone, only RO 20-1724 (Group D) signifi-
cantly (p < 0.01) reduced the leukocyte count compared
with OVA sensitised mice. Treatment with either cilosta-
zol (Group C) or sildenafil (Group E) alone did not alter
the number of leukocytes in the BAL fluid.
When used in combination, only a pairing of RO 20-1724
and sildenafil (Group H) significantly (p < 0.05) reduced
the total leukocyte count compared to OVA sensitised
mice. Combining RO 20-1724 with sildenafil, or cilosta-
zol (Group F), however, produced no significantly differ-
ent response than when RO 20-1724 was used alone. No
additive or synergistic effects were seen with cilostazol
and RO 20-1724 (Group F), or with cilostazol and silde-
nafil (Group G). The combination of all three PDE inhib-
itors (Group I), did not significantly reduce the leukocyte
count compared to OVA sensitised mice.
Differential cell counts
The cells in the BAL fluid from non-OVA challenged mice
were almost exclusively monocytes, with little or no eosi-
nophils present (Figure 1B, Table 3). In OVA-challenged
mice receiving an oral instillation of saline (Group B),
eosinophils comprised 53.7 ± 8.8% of the total cell
number and was highly significantly (p < 0.001) com-
pared to control animals. Treatment with dexamethasone
(Group J) ameliorated the number of eosinophils in the
BAL fluid (4.0 ± 0.9% of total cell number).
Alone, only RO 20-1724 (Group D; 30.7 ± 3.7%) signifi-
cantly (p < 0.05) reduced the number of eosinophils in
the BAL compared to OVA sensitised mice. Treatment
with either cilostazol (42.5 ± 4.3%) or sildenafil (48.9 ±
4.9%) alone did not reduce the number of influxing eosi-
nophils. As was the case for total leukocyte number only
a combination of RO 20-1724 and sildenafil significantly
(p < 0.05) reduced the number of eosinophils in the BAL
compared to OVA sensitised mice.
Cytokine analysis of BAL fluid
Tumour necrosis factor-α measurement
Levels of TNF-α were significantly (p < 0.05) higher in
OVA challenged mice (Group B) compared to non-OVA-
challenged mice (Figure 2A, Table 4) and mice receiving
Dexamethasone. Treatment with either cilostazol (Group
C) or sildenafil (Group E) alone did not alter TNF-α levels
in the BAL fluid. In contrast, RO 20-1724 alone (Group
D) significantly (p < 0.05) reduced the TNF-α levels com-
pared to OVA sensitised mice. Study groups receiving the
combination of PDE inhibitors exhibited no additive or
synergistic effects compared to each PDE inhibitor used
on its own in altering TNF-α levels compared to OVA sen-
sitised mice. In all combinations, the effect of the PDE 4
inhibitor is lost.
Total leukocyte (A) and eosinophil (B) numbers in BAL fluid  recovered from male Balb/c mice following drug treatment Figure 1
Total leukocyte (A) and eosinophil (B) numbers in BAL fluid 
recovered from male Balb/c mice following drug treatment. 
Group A was non-OVA challenged mice orally injected with 
saline. Groups B to J were OVA challenged mice orally 
injected with either saline (Group B) or PDE compound (3 
mg/kg). Group C received cilostazol. Group D received RO 
20-1724. Group E received sildenafil. Group F received 
cilostazol + RO 20-1724. Group G received cilostazol + 
sildenafil. Group H received RO 20-1724 + sildenafil. Group I 
received cilostazol + RO 20-1724 + sildenafil. Group J 
received Dexamethasone. Each study group contained n = 8 
mice. + p < 0.001 compared to non OVA challenged mice 
(Group A), b p < 0.01 compared to OVA challenged mice 
orally gavaged with saline, c p < 0.05 compared to OVA chal-
lenged mice orally gavaged with saline
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Interleukin-4 measurement
Levels of IL-4 were significantly (p < 0.05) higher in OVA
challenged mice compared to the non-OVA-challenged
mice (Figure 2B, Table 4) and mice receiving dexametha-
sone. The administration of either cilostazol (Group C) or
sildenafil (Group E) alone did not alter IL-4 levels in BAL
fluid. In contrast, RO 20-1724 alone (Group D) signifi-
cantly (p < 0.05) reduced the IL-4 levels compared to OVA
sensitised mice. Combining selective PDE inhibitors
exhibited no additive or synergistic effects compared to
each PDE inhibitor used on its own, and in fact reduced
the effect of RO 20-1724 on its own.
Interleukin-5 measurement
Levels of IL-5 were significantly (p < 0.05) higher in OVA
challenged mice compared to the non-OVA-challenged
mice (Figure 2C, Table 4) and in mice receiving Dexame-
thasone. When either cilostazol (Group C) or sildenafil
(Group E) was used alone, this did not alter IL-5 levels in
the retrieved BAL fluid. In contrast to this RO 20-1724
(Group D) alone significantly (p < 0.05) reduced the
amount of IL-5 compared to controls. Again as is observed
with IL-4 and TNF-α the combining of PDE inhibitors
resulted in no additive effects in the reduction of IL-5, and
reduced the effects of the PDE 4 inhibitor on its own.
Serum IgE
Total serum IgE was significantly increased by ovalbumin
sensitisation and challenge in comparison with non-oval-
bumin challenged mice and was not altered by any of the
combinations of compounds, with the exception of dex-
amethasone (data not shown).
Discussion
The benefits of inhibiting PDEs in disease has been
known for many years, however, only recently have drugs
emerged that lack the side effects normally associated with
these drugs [11]. Several new PDE 4 inhibitors, possessing
little side effects, are nearing launch. In our study, we
wished to determine whether there was any synergy in
anti-inflammatory function when PDE inhibitors were
used in combination. An enhancing effect with one of
these combinations, compared to the effects of a PDE 4
inhibitor alone, could suggest this as a possible preferen-
tial treatment for inflammatory conditions. A synergistic
effect could result in the administration of lower doses of
inhibitor, lowering any potential side effects.
A range of PDE inhibitors are about to be launched, or are
already in use. Cilostazol, a PDE 3 inhibitor, is being used
to treat circulatory problems [7]. Sildenafil, a PDE 5 inhib-
itor is used for the treatment of sexual dysfunction and
may potentially be used in cardiovascular disease [30],
and there is the imminent release of new PDE 4 inhibitors
for inflammatory lung disease [11,31]. Due to the success
of these PDE inhibitors in the treatment of varied diseases,
in future years there exists the potential for a patient to be
taking a combination of drugs that will inhibit more than
one PDE family.
The results from this study demonstrate that the PDE 4
inhibitor, RO 20-1724, exhibits potent anti-inflammatory
actions in our murine model of allergic asthma. Neither
the PDE 3 inhibitor, cilostazol, nor the PDE 5 inhibitor,
sildenafil, produced any significant anti-inflammatory
effect. This conflicts with a recent study that indicated
potential benefits of sildenafil in an OVA model [32].
However, their model used different animals and the
administration of the drug was by peritoneal injection,
not oral. In addition, the significant anti-inflammatory
effects of the PDE 4 inhibitor are reduced upon co-admin-
istration with the PDE 3. This is in contrast to many stud-
ies that show that a combined PDE3/4 inhibitor has better
efficacy over a separate PDE 3 or 4 inhibitor. Our study
Table 3: Total leukocyte and differential cell numbers in BAL fluid recovered from male Balb/c mice following drug treatment (×103). 
Each study group contained n = 8 mice.
Study Group Total Monocytes Neutrophil Eosinophil
A 52.50 ± 3.70 52.5 ± 3.6 0.0 ± 0.0 0.0 ± 0.0
B 157.20 ± 16.80 a 77.2 ± 17.9 0.1 ± 0.1 88.5 ± 16.7 a
C 114.10 ± 11.50 65.6 ± 8.2 0.1 ± 0.1 48.1 ± 6.4
D 67.90 ± 11.40 b 52.0 ± 8.4 0.0 ± 0.0 27.3 ± 7.6 c
E 146.90 ± 15.90 73.7 ± 10.0 0.0 ± 0.0 73.1 ± 12.8
F 100.30 ± 13.20 58.3 ± 9.5 0.0 ± 0.0 42.1 ± 5.9
G 165.80 ± 30.80 88.1 ± 15.2 0.0 ± 0.0 77.7 ± 22.7
H 79.90 ± 14.30 c 43.8 ± 6.1 0.0 ± 0.0 36.1 ± 11.5 c
I 113.40 ± 15.90 67.3 ± 12.4 0.0 ± 0.0 46.0 ± 13.8
J 57.50 ± 10.10 b 55.1 ± 9.5 0.0 ± 0.0 2.5 ± 0.7 b
a p < 0.001 compared to non OVA challenged mice (Group A), b p < 0.01 compared to OVA challenged mice orally gavaged with saline (Group B), 
c p < 0.05 compared to OVA challenged mice orally gavaged with saline (Group B)Respiratory Research 2004, 5 http://respiratory-research.com/content/5/1/4
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TNF-α (A), IL-4 (B) and IL-5 (C) concentrations in BAL fluid recovered from male Balb/c mice following drug treatment Figure 2
TNF-α (A), IL-4 (B) and IL-5 (C) concentrations in BAL fluid recovered from male Balb/c mice following drug treatment. Group 
A was non-OVA challenged mice orally injected with saline. Groups B to J were OVA challenged mice orally injected with 
either saline (Group B) or PDE compound (3 mg/kg). Group C received cilostazol. Group D received RO 20-1724. Group E 
received sildenafil. Group F received cilostazol + RO 20-1724. Group G received cilostazol + sildenafil. Group H received RO 
20-1724 + sildenafil. Group I received cilostazol + RO 20-1724 + sildenafil. Group J received Dexamethasone. Each study 
group contained n = 8 mice. + p < 0.001 compared to non OVA challenged mice (Group A), b p < 0.01 compared to OVA 
challenged mice orally gavaged with saline, c p < 0.05 compared to OVA challenged mice orally gavaged with saline
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used a combination of separate PDE 3 and PDE 4 inhibi-
tor and not a dual/mixed compound which posses both
PDE 3 and PDE 4 inhibitory potential.
The anti-inflammatory actions of PDE 4 inhibitors are
well documented both in vitro and in vivo. Selective inhi-
bition of PDE 4 suppresses several eosinophil functions
such as superoxide anion generation [33], adhesion and
migration [34]. Furthermore, PDE 4 inhibitors produce
marked anti-inflammatory actions in several animal mod-
els of allergic asthma [21,22,35].
Glucocorticoids, such as dexamethasone, are often used as
positive control drugs in models of allergic asthma [36].
Dexamethasone inhibits leukocyte migration into sites of
inflammation, predominantly by inhibiting the synthesis
of pro-inflammatory cytokines and chemokines [24]. In
this present study, the effects of RO 20-1724 on leukocyte
infiltration and pro-inflammatory cytokine levels
approached those of dexamethasone, emphasising the
potency of PDE 4 inhibitors as anti-inflammatory agents.
In our study dexamethasone is able to significantly reduce
cell number (total and eosinophil) and inflammatory
mediators (IL-5, IL-4 and TNF-α) better or as good as the
PDE 4 inhibitor used in the study. Long term, high doses
of steroids should be avoided and it may be possible to
use PDE4 drugs in combination with lower doses of ster-
oids. We would propose further study into the effects of
combining PDE 4 compounds and steroids.
All of the parameters of inflammation that were measured
exhibited very similar trends. Thus, the overall pattern of
results for cellular infiltration and the levels of the pro-
inflammatory cytokines, IL-4, IL-5 and TNF-α, in the BAL
fluid were remarkably similar. The Th2-derived cytokines,
IL-4 and IL-5 play a central role in initiating and sustain-
ing an asthmatic response by regulating the production of
IgE as well as the growth, differentiation and recruitment
of inflammatory cells [37]. Indeed, a positive correlation
between lung eosinophilia and levels of IL-4 and IL-5 in
BAL fluid has previously been reported, both in humans
[38] as well as animal models of allergic asthma [39]. Lev-
els of TNF-α are also increased in the airways and BAL
fluid of asthmatics relative to healthy subjects [38,40],
indicating a possible involvement of this pro-inflamma-
tory cytokine in the development of asthma.
Our results are in keeping with previous studies reporting
that PDE 4 inhibitors suppress levels of these cytokines.
Rolipram inhibits TNF-α production from LPS-stimulated
monocytes in vitro [41,42] and from mice in vivo [43]. Fur-
thermore, the second-generation PDE 4 inhibitors, Ariflo
(SB 207499) and Roflumilast both attenuate TNF-α levels
in the BAL fluid from rats and guinea pigs [31] and inhibit
TNF-α, IL-4 and IL-5 production in vitro [44].
In some model systems PDE 3 inhibitors have shown the
ability to reduce selected markers of inflammation either
in vitro or in vivo. Cilostazol has been shown to attenuate
superoxide anion release from guinea pig alveolar macro-
phages [45], while CI-930 was able to decrease eosinophil
influx to a similar extent as rolipram in a Brown Norway
rat model of asthma [22]. However, many groups have
shown that PDE 3 inhibitors offer no anti-inflammatory
potential in vivo, such as siguazodan [37], SK&F 94120
[27] and SK&F 94836 [13]. Possibly, variation in the mod-
els used and inhibition profiles of the these compounds
accounts for these observed differences.
Table 4: TNF-α (A), IL-4 (B) and IL-5 (C) concentrations in BAL fluid recovered from male Balb/c mice following drug treatment. 
Cytokine concentrations were measured using a Biolplex ELISA system. Each study group contained n = 8 mice.
Concentration in BAL fluid (pg/ml)
Study Group TNFα IL-4 IL-5
A 19.9 ± 5.3 10.7 ± 0.5 18.2 ± 0.58
B 43.2 ± 5.1 a 123.6 ± 66.3 a 1077.1 ± 273.5 a
C 41.6 ± 3.6 120.3 ± 5.3 1339.7 ± 120.5
D 22.9 ± 4.6 c 50.7 ± 2.4 c 591.9 ± 108.2 c
E 47.1 ± 5.0 129.4 ± 11.0 1652.9 ± 174.1
F 41.6 ± 6.8 112.8 ± 11.9 1592.5 ± 301.4
G 46.5 ± 6.5 139.3 ± 40.7 1290.3 ± 218.4
H 38.3 ± 7.2 110.1 ± 18.0 1007.6 ± 194.5
I 39.1 ± 7.6 104.8 ± 27.5 1634.9 ± 367.7
J 16.7 ± 3.6 c 15.8 ± 2.1 b 227.9 ± 45.0 b
a p < 0.001 compared to non OVA challenged mice (Group A), b p < 0.01 compared to OVA challenged mice orally gavaged with saline (Group B), 
c p < 0.05 compared to OVA challenged mice orally gavaged with saline (Group B)Respiratory Research 2004, 5 http://respiratory-research.com/content/5/1/4
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Although the anti-inflammatory actions of PDE 5 inhibi-
tors have not been as widely studied as those of PDE 3 or
PDE 4 inhibitors, most studies have shown PDE 5
inhibitors to have little or no effect at reversing inflamma-
tion, although recent reports may suggest otherwise [32].
In a recent study, zaprinast failed to inhibit superoxide
anion release from guinea pig alveolar macrophages
[16,45]. Furthermore, rolipram, but not zaprinast,
reduced eosinophil recruitment into the lungs in sensi-
tised rats [22,46] and guinea pigs [37].
In this present series of experiments, we have used silde-
nafil as the inhibitor of cGMP specific PDE 5. Sildenafil is
reported to be more selective for PDE 5 than zaprinast and
several times more potent, with a low nanomolar IC50
(12). Despite its high selectivity and potency for PDE 5,
sildenafil, when used alone, produced no reduction in
inflammation in our experiments. These findings are in
agreement with the general consensus in that PDE 4
inhibitors are potent anti-inflammatory agents, whereas
PDE 3 and PDE 5 inhibitors have little or no effect.
A major aspect of this study was to examine the possible
interaction between inhibitors of the PDE 3, PDE 4 or
PDE 5 families. More specifically, to examine if a
combination of a PDE 3, PDE 4 or PDE 5 inhibitor pro-
duced any additive or synergistic benefit as opposed to
being used alone. A drawback with the administration of
many PDE 4 selective inhibitors in the treatment of
asthma is their considerable side effects, such as nausea
and stomach acid secretion. Any synergistic or additive
effect between a PDE 4 inhibitor and an inhibitor of PDE
3 or PDE 5, may allow lower doses of drug to be adminis-
tered and thus reduce the severity of any side effects. How-
ever, we were unable to demonstrate any enhancement of
RO 20-1724-mediated anti-inflammation with either
cilostazol, sildenafil or indeed a combination of all three.
In contrast, we observed that combining cilostazol with
RO 20-1724 resulted in a decrease of the anti-inflamma-
tory actions of the PDE 4 inhibitor. This may be due to a
number of reasons such as alterations in PDE4 absorption
across the gastrointestinal tract in the presence of PDE3 or
PDE5 inhibitor or changes in intracellular signalling
pathways.
Conclusions
The PDE 4 inhibitor, RO 20-1724, exhibited potent anti-
inflammatory actions in vivo, whereas the PDE 3 inhibitor,
cilostazol, and the PDE 5 inhibitor, sildenafil, did not.
Instead of observing synergy between PDE 3, PDE 4 and
PDE 5, we observed a loss in the ability of the PDE 4
inhibitor to reduce inflammation in a murine model of
allergic asthma. This finding has potential implications
for patients who may use a combination of PDE inhibi-
tors for a number of different conditions and maybe due
in part to drug-drug interactions. This would not, how-
ever, be expected to occur with a single drug that contains
combined inhibition of PDE 3 and 4. Further research will
be required to determine the cause of these interactions
between the compounds.
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